MediWound (NASDAQ:MDWD) Stock Price Passes Above 50 Day Moving Average – Here’s Why

Shares of MediWound Ltd. (NASDAQ:MDWD) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $16.88 and traded as high as $18.22. MediWound shares last traded at $18.03, with a volume of 39,218 shares traded.

Wall Street Analysts Forecast Growth

MDWD has been the topic of a number of research analyst reports. StockNews.com raised shares of MediWound to a “sell” rating in a research note on Friday, March 21st. Craig Hallum started coverage on shares of MediWound in a research note on Friday, February 28th. They set a “buy” rating and a $39.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of MediWound in a research note on Thursday, March 20th.

MediWound Price Performance

The stock’s fifty day moving average price is $16.88 and its 200-day moving average price is $17.43. The firm has a market cap of $194.87 million, a PE ratio of -6.22 and a beta of 0.50.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.23. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The company had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same quarter in the prior year, the company earned ($0.19) EPS. On average, sell-side analysts anticipate that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

A number of institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its holdings in shares of MediWound by 7.3% during the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after acquiring an additional 739 shares during the period. Russell Investments Group Ltd. raised its stake in MediWound by 154.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,162 shares during the period. Barclays PLC boosted its holdings in MediWound by 11.2% in the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 1,249 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of MediWound by 1,507.1% in the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,703 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of MediWound during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.